LAS VEGAS, NV / ACCESSWIRE / December 8, 2015 / KaleBios Pharmaceuticals shares have gained 1,279% this month. KaloBios has been surging since Shkreli bought a 70% stake in the company, rescuing it from insolvency. Chief Executive Officer Martin Shkreli has been pushing all the right buttons since taking charge of the company early in November, including Friday's announcement that the company will no longer lend stock to people looking to short sell it.
This move was the icing on the cake that has been KBIO's amazing short squeeze, which early investors are certainly realizing monster gains from. It reminds us that in the especially volatile biotech industry all it takes is one event to send a stock soaring.
While KBIO is certainly still moving in the right direction, investors could apply this lesson to their research process, and find the next KBIO.
We think we have a good candidate; Propanc Health Group, Corp.(PPCH).
PPCH recently completed animal efficacy studies. During the course of these studies, PPCH discovered a new target therapeutic dose range using proenzymes for treating cancer. The company filed a patent application in support of this discovery earlier this month.
This is important because it marks the next phase in development of Propanc's pro-enzyme therapy- chiefly its lead drug candidate, PRP- which targets malignant cancer cells through multiple pathways that creates a lasting clinical benefit for the patient. Once commercialized, the drug will be marketed to a $9bn total addressable market.
One of the major reasons for KBIO's initial resurgence was the fact that Martin Shkreli saved the company from insolvency. This is not an issue for PPCH. Propanc announced it secured $4 million from an institutional investor in order to progress PRP towards human trials. It is expected to sufficiently cover the Company's operations over the next 12 months. The global industry for colorectal cancer is projected to reach $8.8 billion by 2020 and the worldwide pancreatic cancer market is expected to surpass $1.2 billion by 2015 representing a significant opportunity for PPCH.
All of this caused SeeThruEquity to 12-month price target of $1.52 per share. From the current price that would be a 3,400% move!
Apparently we aren't the only ones who see PPCH's potential to be the next KBIO.
Read the full report by clicking here: http://bit.ly/1N9W6hV
Take a look at PPCH's stock by Clicking here: http://yhoo.it/1PS2sE9
Review the Company's Investor Presentation: http://bit.ly/1HcXIkz
Here's a few other biotechs worth looking at:
ARCA biopharma Inc. (ABIO) has just released 3rd quarter financials, and they are promising. They reported cash on hand that should bring them through the end of 2017. The company expects the DSMB interim analysis of Phase 2B efficacy data to occur in the first half of 2017.
ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information, please visit www.arcabiopharma.com.
Verastem, Inc. (VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. VSTM also released their 3rd quarter financials expect their existing cash, cash equivalents and investments will allow them to fund their operating plan and capital expenditure requirements at least through the first half of 2017. While some investors are concerned about the losses, it is really par for the course as a biotech in the development phase. Investors entering here could be handsomely rewarded.
Elite Pharmaceuticals, Inc. (ELTP), announced results for the quarter ended September 30, 2015, the second quarter of its 2016 fiscal year. Consolidated revenues for the second quarter of Fiscal 2016 were $2.7 million, a 115% increase on a year-on-year basis. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and a product under review pending approval by the FDA. Elite's lead pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.), and a Hong Kong based company for development of a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.
ARIAD Pharmaceuticals, Inc. (ARIA) announced the initiation of a randomized Phase 3 trial of Iclusig(R) (ponatinib) in second-line patients with chronic myeloid leukemia (CML) in the chronic phase (CP). The OPTIC-2L (Optimizing PonatinibTreatment In CML, Second Line) trial is designed to investigate the efficacy and safety of ponatinib, administered at two starting doses, compared with nilotinib, in patients who are resistant to front-line treatment with imatinib. The primary endpoint of the OPTIC-2L study, now open for patient enrollment, is major molecular response (MMR) by 12 months. Approximately 600 patients are expected to be enrolled at clinical sites in Europe, Asia, Latin America and Canada.
"Physicians treating CML patients will be extremely interested in the outcome of this clinical trial in which ponatinib -- at two different doses -- will be compared to nilotinib in patients resistant to imatinib," stated Dr. D. Selleslag, Department of Hematology, St-Jan Bruges-Ostend Hospital in Belgium.
KBIO the latest example reminding us that the biotech industry offers investors some of the best opportunities at massive windfalls. Propanc (PPCH) looks like it could be the next KBIO investors are looking for. The company is receiving the funding they need, is close to human trials, and prepared for an uplisting that could bring a massive new audience to the stock. Be sure to do your due diligence and prepare to benefit from the biotech boom.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns, Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $19,000 by Propanc Health Group, Corp..
SOURCE: ACR Communication, LLC